​

Cytosorbents (CTSO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CTSO Stock Rating

Cytosorbents stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (92.31%), 1 Hold (7.69%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 1 12 0 Strong Sell Sell Hold Buy Strong Buy

CTSO Price Target Upside V Benchmarks

TypeNameUpside
StockCytosorbents-
SectorHealthcare Stocks 23.68%
IndustryMedical Device Stocks16.34%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.07$1.07$1.07
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25-11--2
May, 25-11--2
Apr, 25-11--2
Mar, 25-11--2
Feb, 25-11--2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 22, 2024EF HuttonBuyBuyhold
Jul 29, 2024EF HuttonBuyinitialise

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.20$-0.57$-0.75$-0.64$-0.38----
Avg Forecast$-0.23$-0.44$-0.89$-0.66$-0.28$-0.24$-0.14$-0.06$0.44
High Forecast$-0.22$-0.42$-0.87$-0.59$-0.27$-0.19$-0.14$-0.06$0.46
Low Forecast$-0.24$-0.46$-0.92$-0.75$-0.29$-0.28$-0.15$-0.06$0.43
Surprise %-13.04%29.55%-15.73%-3.03%35.71%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$39.45M$40.11M$29.36M$36.35M$25.13M----
Avg Forecast$40.80M$42.08M$33.78M$36.61M$39.28M$43.78M$53.70M$64.59M$122.89M
High Forecast$42.58M$43.91M$34.54M$37.60M$39.61M$44.17M$54.10M$66.46M$126.45M
Low Forecast$39.36M$40.60M$33.20M$34.91M$38.95M$43.38M$53.31M$63.24M$120.31M
Surprise %-3.30%-4.68%-13.09%-0.72%-36.04%----

Net Income Forecast

$-45M $-31M $-17M $-3M $11M $25M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-7.84M$-24.56M$-32.81M$-28.51M$-20.72M----
Avg Forecast$-10.33M$-19.61M$-39.74M$-28.51M$-12.57M$-10.49M$-6.28M$-2.69M$19.65M
High Forecast$-9.86M$-18.71M$-38.85M$-26.30M$-12.16M$-8.64M$-6.08M$-2.61M$20.39M
Low Forecast$-10.92M$-20.72M$-40.90M$-33.55M$-12.97M$-12.35M$-6.49M$-2.78M$19.11M
Surprise %-24.14%25.26%-17.44%-64.84%----

CTSO Forecast FAQ

Is Cytosorbents stock a buy?

Cytosorbents stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Cytosorbents is a favorable investment for most analysts.

What is Cytosorbents's price target?

Cytosorbents's price target, set by 13 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $1.07.

How does Cytosorbents stock forecast compare to its benchmarks?

Cytosorbents's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (23.68%) and underperforming the medical device stocks industry (16.34%).

What is the breakdown of analyst ratings for Cytosorbents over the past three months?

  • June 2025: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.

What is Cytosorbents’s EPS forecast?

Cytosorbents's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.24, marking a -36.84% decrease from the reported $-0.38 in 2024. Estimates for the following years are $-0.14 in 2026, $-0.06 in 2027, and $0.44 in 2028.

What is Cytosorbents’s revenue forecast?

Cytosorbents's average annual revenue forecast for its fiscal year ending in December 2025 is $43.78M, reflecting a 74.23% increase from the reported $25.13M in 2024. The forecast for 2026 is $53.7M, followed by $64.59M for 2027, and $122.89M for 2028.

What is Cytosorbents’s net income forecast?

Cytosorbents's net income forecast for the fiscal year ending in December 2025 stands at $-10.494M, representing a -49.35% decrease from the reported $-20.719M in 2024. Projections indicate $-6.284M in 2026, $-2.693M in 2027, and $19.65M in 2028.